Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with No Late Stent Thrombosis or Additional Major Adverse Cardiac Events Out to Three Years

BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac Events (MACE), and no late stent thrombosis in patients treated with either Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System or its MULTI-LINK VISION(R) metallic coronary stent. Additionally, data presented from a meta- (combined) analysis of SPIRIT II and SPIRIT III trials at nine months reaffirmed the superiority of Abbott's XIENCE V compared to the TAXUS(R) paclitaxel-eluting coronary stent system in a variety of measures.

These data were presented today at the EuroPCR meeting in Barcelona.

"The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and ARC definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigator in the SPIRIT trials. "In addition, a meta-analysis of the SPIRIT II and III data again demonstrated the superiority of the XIENCE V system to the TAXUS system in important measures that matter to patients including renarrowing of a treated vessel and major adverse cardiac events."

A meta-analysis of approximately 1,300 patients from the SPIRIT II and SPIRIT III clinical trials conducted by the Cardiovascular Research Foundation indicated that the XIENCE V system demonstrated superiority over the TAXUS stent in angiographic (imaging) and clinical endpoints, with an excellent safety profile.

Specifically, data from the meta-analysis demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System was superior to the TAXUS stent in:

    -- Reducing the occurrence of major 
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Menopause Drugs Price Analysis and Strategies - 2016, provides drug ... answers the following questions: What are the ... positioned in the Global Menopause market? What are the ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... social media management, corporate communications, SEO and cause marketing, is opening an office ... New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... PHILADELPHIA (PRWEB) , ... February 23, 2017 , ... ... risk and uncertainty in clinical trials, today announced that Premier Research, a leading ... management solution. , Clinical trials are becoming increasingly complex, due in part to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez ... has also continued to spiritually evolve, which is the purpose of everyone in this ... Spiritual Truths ” (published by Balboa Press) attempts to guide readers to expand one’s ...
Breaking Medicine News(10 mins):